Abstract: This disclosure provides recombinant placental alkaline phosphatase and highly purified human placental alkaline phosphatase for the treatment of a chemotherapy treated cancer patient to reduce chemotherapy-induced loss of red blood cells, white blood cells, or platelets as well as increase the survival of chemotherapy challenged hematopoietic stem cells, mesenchymal stem cells, or blood cell forming progenitors. Another use of recombinant placental alkaline phosphatase or placental alkaline phosphatase for chemotherapy treated cancer patients is to enhance survival of transplanted hematopoietic and mesenchymal stem cells thereby promoting formation of blood cells. The novelty of this disclosure is using placental alkaline phosphatases to reduce the loss of these cells despite the presence of a highly proteolytic environment in the bone marrow created by chemotherapy.

Abstract: An image processing system and method is provided. The image processing system includes a display, a processor, and a memory. The memory stores processor-executable code that when executed by the processor causes receiving an image of a region of interest of a patient with a medical catheter, tube or line disposed within the region of interest, detecting the medical tube or line within the image, generating a patient coordinate system relative to an anatomy of the patient within the image, generating a combined image by superimposing a first graphical marker on the image that indicates an end of the medical catheter, tube or line, and a second graphical marker on the image that indicates patient coordinate system, and displaying the combined image on the display. In addition, the system assesses common visualizable complications associated with CVC placement, including but not limited to hydrothorax, pneumothorax, pneumomediastinum and CVC position changes between x-rays taken at different times.

Abstract: A method, apparatus, and a computer-readable medium for a web object reputation processing, especially in Web3. The method includes: intercepting data transmitted in a data connection related to a current decentralized application running in a user apparatus, wherein the current decentralized application comprises a frontend implementing a web user interface for a user of the user apparatus, and a backend implemented as a smart contract; determining a reputation of a web object related to the frontend of the current decentralized application; and in response to determining that the reputation of the web object is malicious, blocking the data connection.

Abstract: This invention demonstrates that topically applied placental alkaline phosphatase dispersed in Vaselinum cholesterinatum promotes scar-free healing of acne vulgaris of bacterial origin. Other inflammatory skin conditions caused by bacterial infection and improved by placental alkaline phosphatase include nail infections as well as infections of non-healing diabetic wounds, puncture wounds, surgical wounds and incisions, burns, abrasions, lacerations, ulcers, gum disease, skin tears, or wounds caused by bites or stings. Placental alkaline phosphatase was also found to promote healing of skin lesions, with or without co-administering an antiviral drug, caused by reactivated Varicella zoster (Shingles), Herpes Simplex Virus-1 (oral herpes), or Herpes Simplex Virus 2 (vaginal/genital herpes). In all of these cases, placental alkaline phosphatase was found to significantly reduce irritation or pain associated with bacterial or viral infection and resulting skin damage.

Abstract: Embodiments of the invention include methods for handling packets in a communications network. In one embodiment, a method is implemented in an electronic device. The method includes at a first end of a queue in the electronic device, determining admission of a first packet to the first end of the queue based on a length of the first packet, where when the admission of the first packet would cause the queue to become full, the admission is further based on a packet value of the first packet and a data structure tracking packet value distribution of packets in the queue. The method further includes at a second end of the queue, dropping a second packet from the second end of the queue when the second packet's corresponding packet value is marked as to be dropped in the data structure upon admitting packets to the first end of the queue.

Abstract: A technique for ciphering source data (306) into target data (308) is described. As to a method aspect of the technique, a level (302) of ciphering is determined for the source data (306). A key sequence (304) is generated depending on the determined level (302) of ciphering. The source data (306) and the key sequence (304) are combined resulting in the target data (308).

Abstract: Embodiments of the invention include methods for handling packets in a communications network. In one embodiment, a method is implemented in an electronic device. The method includes at a first end of a queue in the electronic device, determining admission of a first packet to the first end of the queue based on a length of the first packet, where when the admission of the first packet would cause the queue to become full, the admission is further based on a packet value of the first packet and a data structure tracking packet value distribution of packets in the queue. The method further includes at a second end of the queue, dropping a second packet from the second end of the queue when the second packet's corresponding packet value is marked as to be dropped in the data structure upon admitting packets to the first end of the queue.

Abstract: A technique for ciphering source data (306) into target data (308) is described. As to a method aspect of the technique, a level (302) of ciphering is determined for the source data (306). A key sequence (304) is generated depending on the determined level (302) of ciphering. The source data (306) and the key sequence (304) are combined resulting in the target data (308).

Abstract: Methods, systems, and devices for managing an end-device connected to a commodity delivery network. One device includes computer-readable medium containing instructions for managing the end-device and a processor for executing the instructions. The instructions include instructions for detecting tampering of the end-device, ignoring the detected tampering when the end-device has been placed in an ignore mode, and automatically disconnecting the end-device from the commodity delivery system based on the detected tampering when the end-device has not been placed in the ignore mode.

Abstract: Embodiments of the present invention include the use of placental alkaline phosphatase alone or in combination with human transferrin and, optionally, human ?1-antitrypsin to enhance the proliferation and survival of transplanted stem cells and stem cell-derived progenitor cells.

Abstract: A modular illuminating tile (1) comprising a carrier board (8); at least one illuminating element (10) fixed on the carrier board (8); power supply supplying electrical energy to the illuminating element (10), a protective cover associated with the illuminating element (10). The at least one illuminating element (10) is soldered on the carrier board (8); the power supply is connected via wiring (9) to at least one electrical connecting means (11) adjoined mechanically on the carrier board (8), whereas the at least one connecting means (11) is fixed on the carrier board (8) so as to permit arbitrarily mechanical and electrical serial connection of several modular illuminating tiles (1).

Abstract: The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of diabetes in humans. The methods and treatment regimens may be effective to maintain the human's blood glucose level below about 10 mM, and preferably within the normal range of 4 mM to 7 mM. The methods and treatment regimens may be used in combination with administration of known anti-diabetic medicaments. Also provided by the invention is a method for inducing weight loss or reducing an expected weight gain caused by or associated with obesity or Type 2 diabetes. The invention further provides a preparation for administration to a human, the preparation comprising homogeneous purified human placental alkaline phosphatase in a physiologically acceptable carrier.

Abstract: This invention provides an alkaline phosphatase or an active derivative of placental alkaline phosphatase to prevent or reduce one, two, or all three of interrelated metabolic disorders, i.e. insulin resistance, hyperinsulinemia, and dyslipidemia. Alkaline phosphatase or an active derivative of placental alkaline phosphatase is suitable to prevent or reduce diseases and disorders relating to insulin resistance, hyperinsulinemia, and dyslipidemia including type 2 diabetes, epithelial cancers, myopia, acne, acanthosis nigricans, polycystic ovary syndrome, cutaneous papillomas, hypertension, renal dysfunction, microvascular and macrovascular diseases, atherosclerosis, nonalcoholic fat liver, dyslipidemia, sleep-disordered breathing, atherosclerosis, coronary artery (heart) disease, cardiovascular disease, heart failure, accelerated aging, stroke, and neurological diseases such as Alzheimer.

Abstract: Methods, systems, and devices for managing an end-device connected to a commodity delivery network. One device includes computer-readable medium containing instructions for managing the end-device and a processor for executing the instructions. The instructions include instructions for detecting tampering of the end-device, ignoring the detected tampering when the end-device has been placed in an ignore mode, and automatically disconnecting the end-device from the commodity delivery system based on the detected tampering when the end-device has not been placed in the ignore mode.

Abstract: Embodiments of the present invention relate to the use of placental alkaline phosphatase, and other members of the alkaline phosphatase family, to enhance protein synthesis in the muscle as well as the survival of non-cancerous differentiated cells in the muscle, adipose and other tissues. The ability of alkaline phosphatase to selectively enhance the survival of healthy cells and increase protein synthesis has many therapeutic applications. The use of alkaline phosphatase may prevent the loss of body weight and muscle mass typically experienced by diseased (such as cancer) or aging patients, or developing fetuses subjected to harmful conditions, or by patients who are treated with a toxic therapy including chemotherapy.

Abstract: Embodiments of the present invention include the use of placental alkaline phosphatase alone or in combination with human transferrin and, optionally, human ?1-antitrypsin to enhance the proliferation and survival of transplanted stem cells and stem cell-derived progenitor cells.

Abstract: Methods for promoting survival and stimulating proliferation of cells in the epidermis and dermis of undamaged mammalian skin are disclosed. The methods comprise the step of administering to an area of the skin a composition comprising a therapeutically effective amount of human placental alkaline phosphatase, or an active derivative. The composition can be administered topically or by injection. Embodiments of the invention also provide regimens for restoring or maintaining the strength and thickness of aging skin, comprising periodically administering a composition by topical application. Other embodiments of the invention further provide methods for promoting survival and stimulating proliferation of cells in the epidermis and dermis of transplanted skin. A composition for topical application is also provided by some embodiments of the invention.

Abstract: The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of diabetes in humans. The methods and treatment regimens may be effective to maintain the human's blood glucose level below about 10 mM, and preferably within the normal range of 4 mM to 7 mM. The methods and treatment regimens may be used in combination with administration of known anti-diabetic medicaments. Also provided by the invention is a method for inducing weight loss or reducing an expected weight gain caused by or associated with obesity or Type 2 diabetes. The invention further provides a preparation for administration to a human, the preparation comprising homogeneous purified human placental alkaline phosphatase in a physiologically acceptable carrier.

Abstract: A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. They can be used alone or in combination with other therapies to treat cancer and other cell proliferative diseases. Representative compounds of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide and N,N-diethyl-N-allyl-3-(2-methyl-9H-thioxanthen-9-ylidene)-propane-1-aminium bromide, were shown in various tumor models to decrease tumor volume, enhance the effects of other chemotherapeutic agents including cisplatin, reduce chemotherapy-induced loss of body weight, and increase survival of animals co-treated with toxic amounts of cisplatin. These compounds had even greater effects on tumor volume, body weight, and survival when administered together with the human protein placental alkaline phosphatase.

Abstract: The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of diabetes in humans. The methods and treatment regimens may be effective to maintain the human's blood glucose level below about 10 mM, and preferably within the normal range of 4 mM to 7 mM. The methods and treatment regimens may be used in combination with administration of known anti-diabetic medicaments. Also provided by the invention is a method for inducing weight loss or reducing an expected weight gain caused by or associated with obesity or Type 2 diabetes. The invention further provides a preparation for administration to a human, the preparation comprising homogeneous purified human placental alkaline phosphatase in a physiologically acceptable carrier.